Provided by Tiger Fintech (Singapore) Pte. Ltd.

Longeveron Inc

0.8200
-0.0287-3.38%
Post-market: 0.83640.0164+2.00%18:29 EDT
Volume:462.47K
Turnover:379.81K
Market Cap:17.05M
PE:-0.40
High:0.8474
Open:0.8400
Low:0.7999
Close:0.8487
52wk High:2.48
52wk Low:0.6330
Shares:20.80M
Float Shares:16.75M
Volume Ratio:1.02
T/O Rate:2.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0427
EPS(LYR):-2.6164
ROE:-134.52%
ROA:-67.48%
PB:1.35
PE(LYR):-0.31

Loading ...

Company Profile

Company Name:
Longeveron Inc
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
25
Office Location:
Life Science & Technology Park,Suite 520,1951 NW 7th Avenue,Miami,Florida,United States
Zip Code:
33136
Fax:
- -
Introduction:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Directors

Name
Position
Joshua M. Hare
Co-Founder, Chief Science Officer, Executive Chairman of the Board and Director
Khoso Baluch
Director
Neha Motwani
Director
Richard Kender
Director
Rock Soffer
Director
Roger Hajjar
Director
Ursula Ungaro
Director

Shareholders

Name
Position
Than Powell
Interim Chief Executive Officer
Devin Blass
Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing and Controls
Lisa A. Locklear
Chief Financial Officer and Treasurer
Joshua M. Hare
Co-Founder, Chief Science Officer, Executive Chairman of the Board and Director
Nataliya Agafonova
Chief Medical Officer
Paul Lehr
General Counsel and Secretary